7
Safety of androgen therapy in men with prostate cancer

https://doi.org/10.1016/j.beem.2022.101628Get rights and content

Prostate cancer is one of the most frequently diagnosed malignancies in men worldwide and the life expectancy for men with prostate cancer is improving due to advancements in diagnostics and treatment. Male hypogonadism is associated with obesity, diabetes, and other comorbidities and also has been linked with increasing age; the primary therapy modality for this condition is testosterone replacement therapy (TRT). There are concerns that testosterone therapy may cause prostate cancer disease progression. However, contemporary evidence suggests that testosterone replacement therapy may be safe in specific groups of patients with prostate cancer. This chapter will summarise the contemporary literature regarding TRT use in hypogonadal men with prostate cancer, including limitations and future research goals.

Introduction

Male hypogonadism is characterised by the presence of signs and symptoms related to androgen deficiency in conjunction with consistently low testosterone levels, measured on at least two occasions [1]. Testosterone regulates spermatogenesis, secondary sexual functions, erythropoiesis, and bone health [2] and thus hypogonadism is associated with infertility, anaemia, and metabolic disorders [[3], [4], [5], [6]]. Longitudinal studies have shown that testosterone progressively decreases with age [[7], [8], [9]]. The development of low testosterone with age has been described as ‘late-onset hypogonadism’ (LOH) or ‘functional hypogonadism’. LOH has been associated with a higher risk of metabolic conditions such as obesity, cardiovascular disease, and insulin resistance [10]. The European Male Ageing Study (EMAS) was a large, multi-centre cross-sectional study which investigated the prevalence of LOH in a study cohort of 3219 men [11]. The authors observed that the estimated prevalence of LOH was 2.1% in the study cohort, which increased up to 5.9% in patients aged between 70 to 79 years [11]. Although age is a contributing factor to low testosterone levels, the EMAS reported that obesity (body mass index ≥30 kg/m2) was the biggest contributing factor to reduced total testosterone levels compared to the non-obese reference group (mean total testosterone −5.09 nmol/L, p < 0.001) [12].

Testosterone replacement therapy (TRT) is the primary therapy for male hypogonadism, and repletion of androgen levels has been shown to be effective in ameliorating the symptoms of LOH and improving quality of life in some men [1]. Within the last century there has been an increasing interest into both LOH and TRT; the cause of this phenomenon is unclear but it has been attributed to a recent vogue for male rejuvenation [13]. There has been an exponential increase in exogenous testosterone use which has been primarily driven by off-label prescribing. The global testosterone sales have increased by 100-fold over the last three decades and represents an estimated $1.8 billion market [14]. Within this context, the evidence demonstrating the clinical efficacy of TRT in improving quality of life, life expectancy, and optimisation of medical co-morbidities specifically in patients with LOH remains weak [1]. Thus, LOH and exogenous testosterone utilisation represents a growing public health issue [15].

Globally, prostate cancer is one of the most frequently diagnosed malignancies specific to the male sex and third highest diagnosed cancer overall in 2020 [16]. Worldwide, prostate cancer was diagnosed in 1,414,259 men and contributed to 3.8% of all new cancer deaths in 2020 [16]. Prostate cancer was most frequently diagnosed among men aged between 65 and 74 years, with the median age being 67 years at diagnosis [17]. Despite the relatively high incidence rates of prostate cancer, the 5-year survival rate has been shown to be 76–88% [18]. The growth and progression of prostate cancer has been postulated to be reliant on androgens [19] and one of the main therapies to treat metastatic prostate cancer is androgen deprivation therapy [20]. Within this context, it is unclear whether men with prostate cancer and symptomatic hypogonadism should be treated with TRT, and there is a lack of consensus in the current literature [[21], ∗[22], [23]]. Historically, there were concerns that TRT increased the risk and progression of prostate cancer based on the pro-oncogenic effect of androgens in prostate cancer disease pathophysiology [19]. However, there is emerging evidence to suggest that exogenous testosterone use may be safe in certain prostate cancer cohorts, and could ameliorate the symptoms and complications of hypogonadism [24,25].

This chapter will discuss the pathophysiological mechanisms between testosterone and prostate cancer, the contemporary literature regarding the safety of androgen therapy in prostate cancer, and the limitations in current evidence and need for future work.

Section snippets

Pathophysiological mechanisms

The embryological development of the prostate gland is regulated by androgen activity through the androgen receptor (AR) (Fig. 1). Testosterone is converted to 5 alpha-dihydrotestosterone (DHT) via 5alpha-reductase, which binds to the AR to induce transcriptional activity within the prostate [26]. The AR modulates both cell proliferation and apoptosis within the prostate [27]. Huggins and Hodges [19] investigated the effects of androgen deprivation by surgical castration on serum prostatic acid

Androgen saturation theory

The work of Huggins and Hodges [19] has dissuaded many clinicians from prescribing TRT in hypogonadal men with prostate cancer. However, there is emerging data to suggest that in some cohorts of men with prostate cancer TRT may be safe [24,25]. Loeb et al. [39] performed a large case–control study containing 1662 men and observed no overall increase in the risk of prostate cancer with TRT use (odds ratio (OR) 1.03, 95% confidence interval (CI) [0.90, 1.17]). Haider et al. [40] performed a

Contemporary literature

We will discuss the current evidence regarding TRT in men who have undergone curative management of prostate cancer and those who have not been treated or cured of prostate cancer.

Limitations of current evidence and future work

The current evidence for TRT in men with a history of, or concurrent, prostate cancer is predominantly retrospective studies with small cohort sizes. Thus, the quality of evidence is low, and a focus of future research should be the development of large-scale, multicentre randomised controlled trials. In most studies the median follow up is less than five years, and thus future studies should include longer study periods to allow for the recognition of disease progression but also overall

Summary

The role and safety of androgen therapy in men with prostate cancer remains an area of controversy, primarily due to the shift in our understanding of the interplay between androgens and prostate cancer. Moreover, the high incidence of LOH in men with a history of prostate cancer in addition to the lack of evidence and consensus for the safety of TRT in this population has created a clinical dilemma.

The current literature suggests that TRT may be safe in hypogonadal men with previously cured

References (83)

  • M. Khera et al.

    Testosterone replacement therapy following radical prostatectomy

    J Sex Med

    (2009)
  • A.W. Pastuszak et al.

    Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy

    J Urol

    (2013)
  • A.W. Pastuszak et al.

    Testosterone therapy after radiation therapy for low, intermediate and high risk prostate cancer

    J Urol

    (2015)
  • M. Menon et al.

    Biochemical recurrence following robot-assisted radical prostatectomy: analysis of 1384 patients with a median 5-year follow-up

    Eur Urol

    (2010)
  • J.M. Kaufman et al.

    Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men

    J Urol

    (2004)
  • J. Ory et al.

    Testosterone therapy in patients with treated and untreated prostate cancer: impact on oncologic outcomes

    J Urol

    (2016)
  • A.L. Kaplan et al.

    Testosterone therapy in men with prostate cancer

    Eur Urol

    (2016)
  • A. Morgentaler et al.

    Testosterone therapy in men with untreated prostate cancer

    J Urol

    (2011)
  • M. Han et al.

    Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year Johns Hopkins experience

    Urol Clin

    (2001)
  • A.K. Morgans et al.

    Androgen receptor inhibitor treatments: cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer

    Urol Oncol

    (2021)
  • C. Teloken et al.

    Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer

    J Urol

    (2005)
  • M.J. Chisamore et al.

    A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R–3327G and anabolic activity on skeletal muscle mass & function in castrated mice

    J Steroid Biochem Mol Biol

    (2016)
  • G.R. Dohle et al.

    EAU Guidelines: Male Hypogonadism | Uroweb

  • P. Kumar et al.

    Male hypogonadism: symptoms and treatment

    J Adv Pharm Technol Research"" (JAPTR)

    (2010)
  • C.N. Roy et al.

    Association of testosterone levels with anemia in older men a controlled clinical trial

    JAMA Intern Med

    (2017)
  • A. Tsujimura

    Testosterone and metabolic syndrome

    Jpn J Clin Urol

    (2015)
  • M. Punab et al.

    Causes of male infertility: a 9-year prospective monocentre study on 1737 patients with reduced total sperm counts

    Hum Reprod

    (2017)
  • T. Mulligan et al.

    Prevalence of hypogonadism in males aged at least 45 years: the HIM study

    Int J Clin Pract

    (2006)
  • H.A. Feldman et al.

    Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study

    J Clin Endocrinol Metab

    (2002)
  • S.M. Harman et al.

    Longitudinal effects of aging on serum total and free testosterone levels in healthy men

    J Clin Endocrinol Metab

    (2001)
  • E. Barrett-Connor et al.

    Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo study

    J Clin Endocrinol Metab

    (1999)
  • F.C.W. Wu et al.

    Identification of late-onset hypogonadism in middle-aged and elderly men

    N Engl J Med

    (2010)
  • F.C.W. Wu et al.

    Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European male aging study

    J Clin Endocrinol Metab

    (2008)
  • A. Busnelli et al.

    Forever Young’ - testosterone replacement therapy: a blockbuster drug despite flabby evidence and broken promises

    Hum Reprod

    (2017)
  • D.J. Handelsman

    Global trends in testosterone prescribing, 2000-2011: expanding the spectrum of prescription drug misuse

    Med J Aust

    (2013)
  • J.A. McBride et al.

    Testosterone deficiency in the aging male

    Ther Adv Urol

    (2016)
  • H. Sung et al.

    Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

    CA A Cancer J Clin

    (2021)
  • Prostate cancer — cancer stat facts

  • Epidemiology of bladder cancer in Europe

  • C. Huggins et al.

    Studies on prostatic cancer i. the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate

    Cancer Res

    (1941)
  • M.S. Litwin et al.

    The diagnosis and treatment of prostate cancer: a review

    J Am Med Assoc

    (2017)
  • View full text